Orbutopril

This classification denotes an ace inhibitor with the molecular formula C20H34N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GFJ8659TQP, chemically known as (2s,3as,7as)-1-((s)-n-((s)-1-carboxypentyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester but generally known as orbutopril, which bears US NIH Compound Identifier 5745795. European Medicines Agency schedules Orbutopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09456MIG. The term ORBUTOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ORBUTOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule orbutopril under HS 29339990 and SITC 51577. As of Q4 2014, ORBUTOPRIL remains the US FDA Preferred Term for this commodity. Orbutopril bears US NLM identifiers UMLS ID C2983809 and NCI Concept Code C90629. SMILES: O(C(=O)C1N(C2C(C1)CCCC2)C(=O)C(NC(CCCC)C(=O)O)C)CC.